0

    524572

    PHARMAID

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    PHARMAIDS PHARMACEUTICALS LTD. Share Price Today

    Investment Returns

    Over 1 Month 0.08% Over 3 Months 12.34% Over 6 Months -10.63% Over 1 Year -43.96%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    PHARMAIDS PHARMACEUTICALS LTD. fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 119.90
    • P/E Ratio (TTM) -11.83
    • Beta 0.56
    • Book Value / share 15.13
    • Return on equity 0.00%
    • EPS (TTM) 0.00
    • Dividend yield [-]%
    • Net profit/quarter (Cr) -1.31
    info icon alternate text

    PHARMAIDS PHARMACEUTICALS LTD. Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 2.69
    Operating Expense 4.42
    Net Profit -1.31
    Net Profit Margin (%) -48.69
    Earnings Per Share (EPS) -0.37
    EBITDA -1.03
    Effective Tax Rate (%) 22.48
    Particulars DEC 2025 (Values in Cr)
    Revenue 0.83
    Operating Expense 5.13
    Net Profit -3.11
    Net Profit Margin (%) -374.69
    Earnings Per Share (EPS) -0.88
    EBITDA -3.62
    Effective Tax Rate (%) 26.65
    Particulars SEP 2025 (Values in Cr)
    Revenue 5.97
    Operating Expense 11.62
    Net Profit -1.65
    Net Profit Margin (%) -27.63
    Earnings Per Share (EPS) -0.47
    EBITDA -1.25
    Effective Tax Rate (%) 29.18
    Particulars JUN 2025 (Values in Cr)
    Revenue 1.12
    Operating Expense 7.15
    Net Profit -4.36
    Net Profit Margin (%) -389.28
    Earnings Per Share (EPS) -1.24
    EBITDA -4.53
    Effective Tax Rate (%) 23.37
    Particulars MAR 2025 (Values in Cr)
    Revenue 0.13
    Operating Expense 4.92
    Net Profit -3.06
    Net Profit Margin (%) -2353.84
    Earnings Per Share (EPS) -0.86
    EBITDA -1.68
    Effective Tax Rate (%) 19.04
    Particulars MAR 2026 (Values in Cr)
    Revenue 10.60
    Operating Expense 28.33
    Net Profit -10.44
    Net Profit Margin (%) -98.49
    Earnings Per Share (EPS) -2.95
    EBITDA -10.43
    Effective Tax Rate (%) 25.23
    Particulars MAR 2025 (Values in Cr)
    Revenue 2.34
    Operating Expense 11.95
    Net Profit -7.28
    Net Profit Margin (%) -311.11
    Earnings Per Share (EPS) -2.06
    EBITDA -6.23
    Effective Tax Rate (%) 15.25
    Particulars MAR 2024 (Values in Cr)
    Revenue 0.03
    Operating Expense 6.91
    Net Profit -4.95
    Net Profit Margin (%) -16500.00
    Earnings Per Share (EPS) -2.18
    EBITDA -5.58
    Effective Tax Rate (%) 18.71
    Particulars MAR 2023 (Values in Cr)
    Revenue 0.00
    Operating Expense 9.91
    Net Profit -7.56
    Net Profit Margin (%) 0.00
    Earnings Per Share (EPS) -5.86
    EBITDA -9.89
    Effective Tax Rate (%) 23.71
    Particulars MAR 2022 (Values in Cr)
    Revenue 3.94
    Operating Expense 3.81
    Net Profit 0.15
    Net Profit Margin (%) 3.80
    Earnings Per Share (EPS) 0.14
    EBITDA 0.15
    Effective Tax Rate (%) 0.00
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 16.82
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.36
    EBITDA Margin -65.50
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 20.43
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.09
    EBITDA Margin -81.54
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 10.31
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 0.00
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 8.44
    ROE % 1.36
    ROCE % 1.36
    Total Debt to Total Equity 0.00
    EBITDA Margin 3.81
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 18.09
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.39
    EBITDA Margin -266.67
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 20.15
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.14
    EBITDA Margin -18600.00
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 10.46
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 0.00
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 8.44
    ROE % 1.36
    ROCE % 1.36
    Total Debt to Total Equity 0.00
    EBITDA Margin 3.81
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 8.30
    ROE % 0.82
    ROCE % 0.82
    Total Debt to Total Equity 0.00
    EBITDA Margin 1.52
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 2.14
    Total Assets 119.85
    Total Liabilities 119.85
    Total Equity 55.04
    Share Outstanding 3
    Price to Book Ratio 3.80
    Return on Assets (%) -8.99
    Return on Capital (%) -11.94
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 4.80
    Total Assets 91.34
    Total Liabilities 91.34
    Total Equity 70.49
    Share Outstanding 3
    Price to Book Ratio 2.58
    Return on Assets (%) -8.72
    Return on Capital (%) -10.51
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 12.75
    Total Assets 24.58
    Total Liabilities 24.58
    Total Equity 22.46
    Share Outstanding 2
    Price to Book Ratio 2.09
    Return on Assets (%) -30.72
    Return on Capital (%) -33.64
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.40
    Total Assets 11.11
    Total Liabilities 11.11
    Total Equity 8.67
    Share Outstanding 1
    Price to Book Ratio 1.48
    Return on Assets (%) 1.30
    Return on Capital (%) 1.67
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.46
    Total Assets 118.68
    Total Liabilities 118.68
    Total Equity 63.78
    Share Outstanding 3
    Price to Book Ratio 3.80
    Return on Assets (%) -6.13
    Return on Capital (%) -7.05
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 2.45
    Total Assets 85.00
    Total Liabilities 85.00
    Total Equity 71.06
    Share Outstanding 3
    Price to Book Ratio 2.58
    Return on Assets (%) -5.82
    Return on Capital (%) -5.92
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 12.75
    Total Assets 24.54
    Total Liabilities 24.54
    Total Equity 22.42
    Share Outstanding 2
    Price to Book Ratio 2.09
    Return on Assets (%) -30.77
    Return on Capital (%) -33.69
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.40
    Total Assets 11.11
    Total Liabilities 11.11
    Total Equity 8.67
    Share Outstanding 1
    Price to Book Ratio 1.48
    Return on Assets (%) 1.30
    Return on Capital (%) 1.67
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 0.20
    Total Assets 9.11
    Total Liabilities 9.11
    Total Equity 8.52
    Share Outstanding 1
    Price to Book Ratio 1.35
    Return on Assets (%) 1.02
    Return on Capital (%) 1.09
    Particulars MAR 2025 (Values in Cr)
    Net Income -17.27
    Cash from Operations -13.92
    Cash from Investing -12.02
    Cash from Financing 23.35
    Net change in Cash -2.65
    Free Cash Flow -1.44
    Particulars MAR 2024 (Values in Cr)
    Net Income -15.62
    Cash from Operations -10.61
    Cash from Investing -74.99
    Cash from Financing 77.65
    Net change in Cash -7.95
    Free Cash Flow 12.24
    Particulars MAR 2023 (Values in Cr)
    Net Income -9.90
    Cash from Operations -4.01
    Cash from Investing -4.94
    Cash from Financing 21.30
    Net change in Cash 12.34
    Free Cash Flow -2.34
    Particulars MAR 2022 (Values in Cr)
    Net Income 0.14
    Cash from Operations -0.25
    Cash from Investing 0.46
    Cash from Financing 0.00
    Net change in Cash 0.20
    Free Cash Flow -0.25
    Particulars MAR 2025 (Values in Cr)
    Net Income -8.58
    Cash from Operations -7.72
    Cash from Investing -18.90
    Cash from Financing 24.63
    Net change in Cash -1.99
    Free Cash Flow 1.31
    Particulars MAR 2024 (Values in Cr)
    Net Income -6.08
    Cash from Operations -3.44
    Cash from Investing -72.50
    Cash from Financing 65.65
    Net change in Cash -10.29
    Free Cash Flow 12.92
    Particulars MAR 2023 (Values in Cr)
    Net Income -9.90
    Cash from Operations -4.01
    Cash from Investing -4.94
    Cash from Financing 21.31
    Net change in Cash 12.35
    Free Cash Flow -2.34
    Particulars MAR 2022 (Values in Cr)
    Net Income 0.14
    Cash from Operations -0.25
    Cash from Investing 0.46
    Cash from Financing 0.00
    Net change in Cash 0.20
    Free Cash Flow -0.25
    Particulars MAR 2021 (Values in Cr)
    Net Income 0.08
    Cash from Operations 0.40
    Cash from Investing -0.22
    Cash from Financing 0.00
    Net change in Cash 0.17
    Free Cash Flow 0.40
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 48.34 20.06 2.33 370.45 23.12 49.85
    BLISS GVS PHARMA LTD. 477.25 38.43 4.25 5070.49 118.35 552.90
    CIPLA LTD. 1460.00 32.96 3.42 117945.42 1165.55 1672.20
    FERMENTA BIOTECH LTD. 548.50 25.65 3.97 1614.29 256.40 579.65
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 48.34 33.80 6.22 370.45 23.12 49.85
    AMRUTANJAN HEALTH CARE LTD. 530.10 23.76 4.13 1532.55 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8077.30 105.56 23.13 20193.25 7630.00 9850.00
    BLISS GVS PHARMA LTD. 477.25 51.65 4.38 5070.49 118.35 552.90

    PHARMAIDS PHARMACEUTICALS LTD. shareholding pattern

    Holding
    67.01%
    32.98%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    PHARMAIDS PHARMACEUTICALS LTD. Technicals Summary

    34.00 -2.94 redarrow
    red-green-graph indicator
    2 Bearish
    14 Bullish
    • 5 Days 34.00
    • 26 Days 32.60
    • 10 Days 33.10
    • 50 Days 32.40
    • 12 Days 32.90
    • 100 Days 33.50
    • 20 Days 32.70
    • 200 Days 38.00
    35.34 PIVOT
    First Support 34.39 First Resistance 35.99 Second Support 33.74 Second Resistance 36.94 Third Support 32.79 Third Resistance 37.59
    RSI 61.74 ADX 9.86 MACD 0.35 Williams % R -18.68 Commodity Channel Index (CCI) 140.61
    Date 2026-08-10 Week 15462.00 Same Day 13518.00 Month 7698.00
    1 Year 0.56 3 Year 0.22
    Over 1 Month
    0.08% down
    Over 1 Year
    -43.96% down
    Over 3 Months
    12.34% down
    Over 3 Years
    0.86% down
    Over 6 Months
    -10.63% down
    Over 5 Years
    18.64% down

    PHARMAIDS PHARMACEUTICALS LTD. Corporate Actions

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Pharmaids Pharmaceuticals Ltd?

    Answer Field

    Pharmaids Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 34.00 as on Aug 11 2026 03:30 PM.

    What is the Market Cap of Pharmaids Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Pharmaids Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 119.90 as on Aug 11 2026 03:30 PM.

    What is the 52 Week High and Low of Pharmaids Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Pharmaids Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 67.50 and ₹ 25.60.

    What is 1 year return for Pharmaids Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been -43.96%.

    What is the P/E Ratio of Pharmaids Pharmaceuticals Ltd Share?

    Answer Field

    As on Aug 11 2026 03:30 PM the price-to-earnings (PE) ratio for Pharmaids Pharmaceuticals Ltd share is -11.83.

    What is the PB ratio of Pharmaids Pharmaceuticals Ltd Share?

    Answer Field

    As on Aug 11 2026 03:30 PM, the price-to-book (PB) ratio for Pharmaids Pharmaceuticals Ltd share is 15.13.

    How to Buy Pharmaids Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Pharmaids Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Pharmaids Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Pharmaids Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Pharmaids Pharmaceuticals Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |